Vir Biotechnology/$VIR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Ticker

$VIR
Sector
Primary listing

Employees

408

VIR Metrics

BasicAdvanced
$727M
-
-$4.01
1.28
-

What the Analysts think about VIR

Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.

Bulls say / Bears say

Held $1.02 billion in cash, cash equivalents, and investments as of March 31, 2025, ensuring funding for core programs and strategic priorities into mid-2027 (Vir IR)
Enrolled the first patient in the ECLIPSE Phase 3 registrational program for chronic hepatitis delta in Q1 2025, advancing a first-in-class combination with Breakthrough and Fast Track designations (Vir IR)
Continued to escalate dosing of dual-masked PRO-XTEN T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA), with early safety data confirmed and Phase 1 for VIR-5525 (EGFR) set to start in H2 2025 (BioSpace)
Total revenue dropped 94.6% to $3.0 million in Q1 2025, down from $56.4 million a year earlier, due to the expiration of GSK collaboration milestones and deferred revenue recognition (Vir IR)
Net loss increased to $121.0 million, or $0.88 per share, in Q1 2025 versus $65.3 million, or $0.48 per share, in Q1 2024, reflecting higher cash burn and increased R&D spending (Vir IR)
R&D expenses rose 18.5% year-over-year to $118.6 million in Q1 2025, driven by a $30 million payment to Alnylam and the launch of the Phase 3 ECLIPSE program, pressuring near-term profitability despite efforts to cut costs (Vir IR)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

VIR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VIR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VIR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs